|Bid||20.18 x 900|
|Ask||34.69 x 1200|
|Day's Range||34.10 - 34.77|
|52 Week Range||27.11 - 39.86|
|Beta (5Y Monthly)||0.24|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 25, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||38.39|
Premier Inc., through its ProvideGx® program, has partnered with Somerset Pharma, LLC., to supply sulfamethoxazole/trimethoprim.
Premier Inc. (NASDAQ: PINC), a leading healthcare improvement company, today announced a data licensing agreement with the National Institutes of Health (NIH). Under the terms of the agreement, researchers in the Critical Care Medicine Department at the NIH Clinical Center, the largest research hospital in America, will be granted access to the Premier Healthcare Database (PHD) to conduct research on the impact of COVID-19 on patients across the U.S.
Premier Inc. has enhanced its crisis forecasting and planning technology to predict the COVID-19 census for any U.S. hospital on a given day.